Habib Torfi, CEO and Principal Founder of Invitrx, Inc, a privately held tissue engineering and stem cell corporation based in Mission Viejo, CA, announced the formation of a new company, DNA-Invitrx, Inc. that has been co-founded with the DNA Corporation of Guadalajara, Mexico. Invitrx will first bring its patented skin graft product to the Guadalajara market, followed by rapid expansion into the other major Mexican markets. The Invitrx skin grafts have been successfully used on burn patients at a major metropolitan Guadalajara hospital, were patients were observed to quickly heal and have greatly reduced pain when the Invitrix skin grafts were applied. Ahmed Al-Qahtani, M.D. a professor of medicine at UAE’s medical school and a researcher at the University of California, Irvine, will serve as Chief Medical Officer, and Greg Maguire, PhD, a former professor at the University of California, San Diego School of Medicine, serves as Chief Scientific Officer and VP of Business Development. Quoting CEO Habib Torfi, “We chose to locate in Guadalajara and partner with the DNA Corporation because of the world class infrastructure in Guadalajara, including several highly regarded hospitals that serve the Guadalajara regional area, and because of close proximity to our first major markets in Mexico, including Guadalajara and Mexico City, a market that is vastly underserved and conservatively estimated to be valued at 200 million USD per year.” DNA-Invitrx, Inc. is initially producing skin grafts for leg ulcers, burns, and trauma and providing these grafts to leading medical doctors in the Mexican market. Dr. Maguire added, “Invitra CS, our composite skin graft product, is a living matrix formed by fibroblasts and supporting scaffolding composed of collagen and a specialized mesh. Because the Invitra CS is a highly viable living network, the Invitrx graft is the most effective means to close wounds because of the graft’s ability to communicate wound healing signals to surrounding tissue.” Dr. Al Qahtani stated that “because of the special wound healing signals released from the Invitrx skin graft, we observe in the clinic a superior rate of healing and reduction in pain in our patients compared to that of other products.” Dr. David Medina, a reconstructive plastic surgeon and Director of the burn unit at Guadalajara Civic Hospital, observed that “with Invitra CS we have demonstrated a new cutting-edge technique to better close wounds, and we are pleased that Guadalajara will be one of the first clinical sites in the world to offer this advanced technique to alleviate the pain and suffering of wounds associated with diabetic ulcer, trauma, and burns.” Contact: |